secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeoVax Labs, Inc. (GOVX)
CIK:        0000832489
Form:       8-K
Filed at:   2026-04-15T23:59:59+00:00
Accession:  0001437749-26-012435
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeoVax reports 2025 net loss $21.5M; Phase 3 trial for mpox vaccine planned H2 2026
--------------------------------------------------------------------------------

- Net loss $21.5M ($22.40/share) vs $25.0M ($120.46/share) in 2024; revenue $2.5M from BARDA contract.
- Cash $3.1M at Dec 31, 2025; R&D expenses $18.1M (down from $23.7M); BARDA contract terminated Apr 2025.
- GEO-MVA Phase 3 trial to start H2 2026; EMA supports streamlined development without Phase 1/2.
- GEO-CM04S1 COVID vaccine Phase 2 data in 2026; Gedeptin oncology Phase 2 planned for 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/832489/000143774926012435/0001437749-26-012435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/832489/000143774926012435/govx20260415_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-012435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer